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A sensitive and selective ultra-high performance liquid chromatography–tandem
mass spectrometry (UPLC–MS/MS) method for the simultaneous determination of
seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyro-
sine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabrafenib, vemurafenib and
regorafenib, plus its active metabolite regorafenib M2) in EDTA plasma was devel-
oped and validated. Stable isotope-labelled internal standards were used for each
analyte. A simple protein precipitation method was performed with acetonitrile. The
LC–MS/MS system consisted of an Acquity H-Class UPLC system, coupled to a Xevo
TQ-S micro tandem mass spectrometer. The compounds were separated on a Waters
CORTECS UPLC C18 column (2.1 × 50 mm, 1.6 μm particle size) and eluted with a
gradient elution system. The ions were detected in the multiple reaction monitoring
mode. The method was validated for cobimetinib, cabozantinib, dabrafenib, niraparib,
olaparib, vemurafenib, regorafenib and regorafenib M2 over the ranges 6–1000,
100–5000, 10–4000, 200–2000, 200–20,000, 5000–100,000, 500–10,000 and
500–10,000 μg/L, respectively. Within-day accuracy values for all analytes ranged
from 86.8 to 115.0% with a precision of <10.4%. Between-day accuracy values
ranged between 89.7 and 111.9% with a between-day precision of <7.4%. The devel-
oped method was successfully used for guiding therapy with therapeutic drug moni-
toring in cancer patients and clinical research programs in our laboratory.
K E YWORD S
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1 | INTRODUCTION
Over the last two decades, the development of targeted oral antican-
cer drugs has increased strongly and this is expected to continue.
After the approval of the first oral tyrosine kinase inhibitor imatinib in
2001, various oral kinase inhibitors have been approved, specifically
targeting one or multiple protein kinases (Dagher et al., 2002;
Roskoski, 2019). Protein kinases play a key role in activating proteins
that are involved in signal transduction pathways that regulate
cell survival, proliferation and differentiation. In patients with
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malignancies, these pathways are often upregulated as they drive
tumour growth, proliferation and angiogenesis (Ardito, Giuliani, Per-
rone, Troiano, & Lo Muzio, 2017). Hence, inhibitors of protein kinases
in these pathways comprise an important therapeutic intervention
(Zhang, Yang, & Gray, 2009). Protein kinase inhibitors that have been
approved recently and are used in our clinic include vemurafenib,
dabrafenib, cobimetinib, regorafenib and cabozantinib. Recently, a
new group of targeted oral anticancer drugs was introduced. Olaparib
and niraparib are inhibitors of the poly ADP ribose polymerase 1
(PARP-1). PARP is essential for the repair of single-strand DNA breaks
via the base excision pathway. Inhibiting PARP results in double-
strand DNA breaks which result in cell death (Ashworth, 2008).
Although PARP inhibitors were initially intended for use in cancers
driven by BRCA1 or 2 mutations, these drugs are now also being
investigated for use in homologous repair-deficient tumors lacking
BRCA1 and 2 mutations and in combination with chemotherapy or
radiation to enhance the DNA-damaging effects (Cesaire et al., 2018;
Lu, Liu, Pang, Pacak, & Yang, 2018).
PARP inhibitors and tyrosine kinase inhibitors are registered in a
fixed dose, which means each patient receives the same dose regard-
less of body size differences. For some of these drugs, a clear rela-
tionschip between drug exposure and efficacy has already been
described. For instance, for patients treated with cabozantinib, greater
antitumour acitivity was observed for patients with a steady-state
concentration >750 μg/L (Lacy et al., 2018). For vemurafenib, a lower
risk of disease progression was seen for patients with a median
plasma concentration of 42,000 μg/L during the first year of treat-
ment (Goldwirt et al., 2016). Patients treated with these drugs will
probably benefit from routine therapeutic drug monitoring to achieve
these target levels. For the other drugs, the relationship between drug
exposure and response needs to be further elucidated. In addition,
measuring the exposure of these drugs can be of help for dose adjust-
ment decisions in the presence of drug–drug interactions or co-mor-
bidities, as these drugs have a narrow therapeutic window and high
inter-patient variability.
Therefore, there is a need for pharmacokinetic evaluation both in
clinical studies and for individual patients. Our laboratory has previ-
ously implemented a bioanalytical method for the measurement of
imatinib, sunitinib, desethyl sunitinib and pazopanib in a single run for
routine patient care and clinical studies (van Erp et al., 2013). Since
novel oral oncolytics have become available, an additional method
had to be developed to analyse these drugs, preferably in a single run.
Numerous LC–MS/MS methods have been described for quanti-
fication of the individual compounds or a combination of cobimetinib
(Cardoso et al., 2018; Deng et al., 2014; Huynh et al., 2017; Rousset
et al., 2017), cabozantinib (Abdelhameed, Attwa, & Kadi, 2017),
dabrafenib (Cardoso et al., 2018; Huynh et al., 2017; Merienne et al.,
2018; Rousset et al., 2017), niraparib (van Andel et al., 2017), olaparib
(Nijenhuis, Lucas, Rosing, Schellens, & Beijnen, 2013; Pressiat et al.,
2018), vemurafenib (Cardoso et al., 2018; Huynh et al., 2017;
Nijenhuis, Rosing, Schellens, & Beijnen, 2014; Rousset et al., 2017)
and regorafenib (Cardoso et al., 2018; Huynh et al., 2017; Luethi et
al., 2014; Merienne et al., 2018; van Erp et al., 2013) in human plasma.
However, a quantification method combining all of the above men-
tioned oncolytics in a single run has not been published yet.
Our objective was to develop and validate a sensitive and selec-
tive bioanalytical method by ultra-high performance liquid chromatog-
raphy–tandem mass spectrometry (UPLC–MS/MS) for the
simultaneous quantification of seven targeted oral oncolytics
(cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib,
vemurafenib and regorafenib plus its metabolite regorafenib M2) in
human EDTA plasma.
2 | MATERIAL AND METHODS
2.1 | Chemicals and reagents
Regorafenib (RGF), regorafenib M2 (RGF M2), olaparib (OPR),
vemurafenib (VMF), cobimetinib (CBT), niraparib (NPR), cabozantinib
(CBZ) and dabrafenib (DBF) were obtained from Bio-Connect BV






cabozantinib and 2H9-dabarefenib used as internal standards, were
acquired from Alsachim (Illkirch, France). Dimethyl-sulfoxide (DMSO,
Seccosolv) and acetonitrile (ACN, Lichrosolv) were purchased from
Merck (Darmstadt, Germany). Formic acid was obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands). High-purity Milli-Q water was
produced using a MilliQ Gradient water purification system (Millipore,
Amsterdam, The Netherlands). Ethylenediaminetetraacetic acid
(EDTA) plasma was prepared from EDTA whole blood obtained from
Sanquin (Amsterdam, The Netherlands).
2.2 | Chromatographic conditions
The LC–MS/MS system consisted of an Acquity H-Class UPLC sys-
tem, coupled to a Xevo TQ-S Micro Tandem Mass Spectrometer
(Waters, Wilford, MA, USA). Chromatographic separation was per-
formed by injecting 10 μL supernatant onto a Cortecs UPLC C18 col-
umn (2.1 × 50 mm, 1.6 μm particle size, Waters). Mobile phase A
consisted of 0.1% formic acid in water (Milli-Q) and mobile phase B
consisted of 0.1% formic acid in ACN. The following gradient was
used (time: %A/%B): 0–0.1 min: 80/20 5.0 min: 50/50 6.0 min: 10/
90 6.0–7.0 min: 80/20. The flow rate was 0.8 ml/min. The column
temperature was kept at 50C and the autosampler temperature at
room temperature (25C). The LC eluate was directed into a tandem
quadruple, atmospheric pressure ionization mass spectrometer (TQ-S
detector, Acquity, Waters, Milford, MA, USA) equipped with an
electrospray ionization source.
2.3 | Mass spectrometric conditions
The mass spectrometer was run in the positive ion mode and config-
ured in multiple reaction monitoring mode for detection of RGF, RGF
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M2, OPR, VMF, CBT, NRP, CBZ, DBF and their isotope-labelled ana-
logues. Figure 1 shows the chemical structures of all eight analytes
and their selected mass transitions and proposed m/z fragments.
Capillary voltage, cone voltage, collision energy and dwell time
were optimized using Masslynx™ Intellistart Software (version 4.1,
Waters, Etten-Leur, The Netherlands). The following settings for the
Xevo TQ-S micro mass spectrophotometer were used: source temper-
ature 150C, desolvation temperature 500C, nitrogen gas flow
1000 L/h and capillary voltage 4 kV. MS settings are shown in
Table 1.
2.4 | Preparation of stock solutions, calibration
standards, quality control samples and internal
standard solution
Stock solutions were prepared in DMSO at a nominal concentration
of 1000 mg/L (RGF, RGF M2, CBT, NRP, CBZ and DBF) or
10,000 mg/L (OPR and VMF). A series of eight working solutions for
each analyte, except CBZ, was prepared by diluting the stock solu-
tions in DMSO. During development, the limit of quantification of
cabozantinib was expanded from 300 to 100 μg/L to cover the full
range of clinically relevant plasma concentrations. Consequently, for
cabozantinib, nine working solutions were prepared by diluting the
stock solutions in DMSO. The preparation of the working solutions is
shown in Supplementary Table 1. These working solutions were
diluted 10-fold in human EDTA plasma to yield the concentrations of
the calibrations curve as listed in the Table 2.
Quality control (QC) samples were prepared in a similar way,
using stock solutions independently prepared from the stock solutions
used for the calibration samples. For cabozantinib an additional extra
low quality control sample (QCXL) was included. The concentrations
of the QC samples in human EDTA plasma are listed in Table 2.
The internal standard stock solutions were prepared in DMSO at
a nominal concentration of 1000 mg/L for each isotope-labelled ana-
lyte. For the precipitation solutions to which the internal standards
are added, the isotope-labelled stock solutions of CBT and NRP were
diluted 10-fold. Subsequently, precipitation solutions were prepared
F IGURE 1 Chemical structures and
proposed m/z fragments of all eight
analytes
KRENS ET AL. 3 of 12
by adding 80 μl (CBZ, DBF, NRP), 160 μl (RGF, CBT) and 400 μl (OPR,
VMF) of the internal standard stock solutions of the isotope-labelled
compounds to 100 ml ACN.
2.5 | Sample preparations
Samples were mixed for 5 min and subsequently centrifuged for 5 min
at 19,000g. Protein precipitation as sample preparation was per-
formed by adding 200 μl of the precipitation reagent to 50 μl of EDTA
plasma into a 1.5 ml polypropylene microcentrifuge tube. After
vortex-mixing for 2 min, samples were centrifuged for 5 min at
19,000g. A volume of 20 μl of the supernatant was transferred to an
autosampler vial, diluted 10-fold with water and vortex-mixed for
5 min. Subsequently, 10 μl was injected into the UPLC–MS/MS.
2.6 | Validation procedures
Method validation was performed in accordance with the “Guideline
on bioanalytical method validation” of the European Medicines
Agency (EMA) (EMA, 2012).
2.6.1 | Selectivity and carryover
Interference from endogenous compounds was investigated by ana-
lysing blank human EDTA plasma samples of six different individuals.
Absence of interfering components was accepted when the response
was <20% of the lower limit of quantification (LLOQ) for all analytes
and <5% for the IS.
Carryover was assessed by injecting a blank human EDTA plasma
sample without IS after injection of the higher limit of quantification
(HLOQ) containing all eight analytes and IS. This step was repeated
five times. To meet the requirements of the EMA guidelines, carryover
in the blank sample should be <20% of the LLOQ of each drug
and <5% of the IS.
2.6.2 | Accuracy and precision
Accuracy and within-day and between-day precision were determined
by analysing spiked EDTA plasma samples at the LLOQ and HLOQ in
addition to three different QC levels (H-M-L) in 5-fold on three differ-
ent days. For cabozantinib QCXL was also included in this analysis.







RGF 10,000; 8300; 6640; 5000; 3500;
2000; 1000; 480
7500; 4500; 1500
RGF-M2 10,000; 8300; 6640; 5000; 3500;
2000; 1000; 480
7500; 4500; 1500
OPR 20,000; 16,600; 13,200; 10,000;
6800; 4000; 2000; 200
15,000; 9000; 600
VMF 100,000; 83,400; 66,800; 50,000;
35,000; 20,000; 10,000; 4800
75,000; 44,000;
15,000
CBT 1000; 840; 640; 500; 340; 200;
100; 6
740; 400; 20
DBF 4000; 3340; 2640; 2000; 1340;
800; 400; 10
3000; 1500; 30
CBZ 5000; 4160; 3320; 2500; 1840;
1000; 500; 500; 100
3760; 2000; 1500;
300
NRP 2000; 1660; 1320; 1000; 760;
400; 200; 300
1500; 800; 400




(min) Analyte (m/z) Internal standard (m/z)
Dwell (s) Cone (V) Collision (V)Start End Precursor (Q1) Product Ion (Q3) Precursor (Q1) Product Ion (Q3)
NRP 0.00 0.75 321 205 327 211 0.099 44 40
OPR 0.75 1.75 435 281 443 281 0.099 36 30
CBZ 1.75 2.75 502 323 506 323 0.037 40 36
CBT 1.75 2.75 532 140 538 140 0.060 54 18
DBF 3.25 4.50 520 307 529 316 0.024 72 36
RGF M2a 3.25 4.50 499 304 487 292 0.024 36 36
VMF 4.50 5.50 490 383 496 389 0.017 90 26
RGF 4.50 5.50 483 288 487 292 0.017 56 22
Abbreviations: RGF, regorafenib; RGF M2, regorafenib M2; OPR, olaparib; VMF, vemurafenib; CBT, cobimetinib; NPR, niraparib; CBZ, cabozantinib; DBF,
dabrafenib.
aFor RGF M2, isotope-labelled RGF was used as an internal standard.
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The accuracy was calculated as the average percentage of the
nominal concentration. For the within-day precision the highest
coefficient of variation (CV) of the three runs was used. One-way
analysis of variance (ANOVA) was used to assess the between-day
precision for each of the five concentrations. The error mean
square or mean square within groups (ErrMS), the day mean square
or mean square among groups (DayMS), and the grand mean (GM)
of all 15 measurements across the three run days were obtained
from the ANOVA. The estimate of the between-day precision at
every concentration was calculated as follows, in which n is the
number of replicate measurements within each day:
Between-day precision = ([(DayMS − ErrMS)/n]0.5/GM) × 100%.
The within-day and between-day precision was expressed as
relative standard deviation (RSD). For the lower limit of quantifica-
tion, the percent deviation from the nominal concentration and the
RSD should be <20%. For all other concentrations the percentage
deviation from the nominal concentration and the RSD should be
<15%.
2.6.3 | Extraction recovery
Total extraction recovery was determined for all analytes by compar-
ing response ratios of extracted plasma samples with those obtained
by direct injection of the same amount of drug in mobile phase at
three concentrations (QCH, QCM and QCL) in duplicate. For
cabozantinib total extraction recovery was additionally determined for
QCXL in duplicate. According to our internal aim, the recovery ratios
should be >70% and preferably be constant over the concentration
range.
2.6.4 | Dilution integrity
Dilution integrity was investigated for samples with concentrations
above the calibration range by analysing samples at a concentrations
1.5 times the HLOQ. Samples were diluted 2 and 4 times, respec-
tively, with blank EDTA plasma. Each dilution was carried out 5-fold
and compared with the nominal concentration. Accuracy and preci-
sion should be <15%.
2.6.5 | Matrix effect
The matrix effect was determined for all eight components and the
labelled IS in six different blank EDTA plasma batches from individ-
ual donors. After precipitation with acetonitrile samples were
spiked with the compounds at two concentrations (QCL and QCH)
and the IS. The matrix factor (MF) was defined by calculating the
ratio of the peak area in the presence and absence of matrix. The
coefficient of variation (CV) of the IS normalized MF, calculated by
dividing the MF of the components by the MF of the IS, should
be within 15%.
2.6.6 | Stability
Stability of the stock solutions in DMSO was tested at −40C. Spiked
samples at three concentrations (QCL, QCM, QCH) were used for
determining the stability in plasma (−40C, 4C and room tempera-
ture). Stability during sample handling was verified by subjecting a
range of spiked samples to three freeze–thaw cycles (stored at
−40C). Additionally, autosampler stability over the range of LLOQ to
HLOQ of processed samples (4C) was tested. Stability of individual
patient samples was determined in samples that were collected for
routine patient care and were stored at −40C after the initial analy-
sis. Samples within the described limits of accuracy (±15%) were con-
sidered to be stable.
3 | RESULTS
3.1 | Method development
The chromatographic separation for the eight analytics is shown in
Figure 2. Figure 2 shows the reconstructed ion chromatogram overlay
for the medium calibration sample of the eight analytes. This clearly
depicts the wide range of signal intensity, mainly caused by differ-
ences in concentrations measured, encountered in this integrated
method. Run time for the final assay was 7 min.
3.2 | Method validation
3.2.1 | Calibration curve
RGF, RGF M2, OPR, VMF, CBT, NRP, CBZ and DBF were quanti-
fied in plasma by describing the peak area ratio to the internal
standard vs. the nominal concentration. A quadratic curve with 1/x
as weighting factor proved to result in the best fit. The range of
the calibration curve was chosen to cover the expected clinically
relevant plasma concentrations. The calibration range covers the
range of 500–10,000 μg/L for regorafenib and regorafenib M2,
200–20,000 μg/L for olaparib, 5,000–100,000 μg/L for vemurafenib,
6–1000 μg/L for cobimetinib, 300–2000 μg/L for niraparib, 10–
4000 μg/L for dabrafenib and 100–5000 μg/L for cabozantinib,
respectively.
3.2.2 | Selectivity and carryover
Multiple reaction monitoring traces of all six blank EDTA plasma sam-
ples from individual donors showed the absence of interference as
responses were <20% of the LLOQ and 5% of the IS. Chromatograms
of all analytes at the LLOQ level and their respective blank human
EDTA sample are shown in Figure 3.
Carryover in the blank sample after injection of the HLOQ sample
was <20% of the LLOQ for each drug and <5% of the IS.
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3.2.3 | Accuracy and precision
As presented in Table 3, the accuracy and the within- and between-
day precision over the calibration range (LLOQ, QCXL, QCL, QCM,
QCH and HLOQ) met the requirements of a RSD <20% for the LLOQ
and a RSD <15% for all other concentrations. Within-day accuracy
values for all analytes ranged from 86.8 to 115.0% with a precision
<10.4%. Between-day accuracy values ranged between 89.7 and
111.9% with a within-day precision <7.4%.
3.2.4 | Recovery
The total extraction recovery ratios, with protein precipitation used
for sample preparation, were >70% and constant over the range of
concentrations for all analytes.
3.2.5 | Dilution integrity
Two- and 4-fold diluted samples of 1.5*HLOQ were quantified for all
analytes. The accuracy for both dilutions ranged from 99.0 to 112.6%
for all analytes, except for regorafenib M2 and the 4-fold dilution of
dabrafenib. An accuracy of 116.4 and 119.5% was observed for the 2-
and 4-fold dilution of regorafenib M2, respectively. For dabrafenib
the accuracy for the 4-fold dilution was 125.2%. The precision was
<3.0% for all analytes. Consequently, dilution integrity was validated
for both dilutions of RGF, OPR, VMF, CBT, NRP, CBZ, only the 2-fold
dilution of DBF and not for the dilutions of RGF M2.
3.2.6 | Matrix effect
The CV of the IS-normalized matrix effect calculated from the six
plasma batches at both concentrations (QCL, QCXL for cabozantinib,
and QCH) was <8.2% for all analytes.
3.2.7 | Stability
Short-term stability of spiked plasma samples was found to be stable
after storage at 4C and room temperature for at least 14 days. Stabil-
ity analysis for sample handling showed that samples were stable for
F IGURE 2 Representative reconstructed ion
chromatogram overlay of a mixture of the medium
quality control samples. 1, niraparib; 2, olaparib; 3,
cobimetinib; 4, cabozantinib; 5,dabrafenib; 6,
regorafenib M2; 7, vemurafenib; 8, regorafenib
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at least three freeze–thaw cycles. Processed samples were stable for
at least 9 days in the autosampler (4C).
Long-term stability of the spiked plasma samples stored at −40C
was proven for at least 20 weeks. Stock solutions stored at −40C
remained stable for at least 4.8 months. Samples of patients treated
with cabozantinib (n = 2), dabrafenib (n = 6), olaparib (n = 2),niraparib
(n = 2) or vemurafenib (n = 1) were stable at −40C for at least 111,
132, 120, 183 and 132 days, respectively. Stability data are presented
in Tables 4 and 5.
3.3 | Clinical application
This validated assay is routinely used in our clinic for pharmacoki-
netic monitoring in patients with cancer. For the anticancer drugs
with well-defined target trough levels, therapeutic drug monitoring
is implemented as routine service. For anticancer drugs without an
established exposure–response relationship, pharmacokinetic evalu-
ation may be performed occasionally for efficacy, toxicity and/or
compliance concerns. Our clinic was consulted to determine
whether there was sufficient exposure in a patient with progressive
disease during treatment with olaparib 400 mg capsules twice daily.
The plasma concentration–time curve for olaparib in this patient is
included in Figure 4. Pharmacokinetic parameters were comparable
with the pivotal registration data (Mateo et al., 2016), confirming
adequate exposure. Reconstructed ion chromatograms of patients
samples and the internal standard for cabozantinib, olaparib,
niraparib and vemurafenib have been included in Supplementary
Figure 1.
F IGURE 3 Reconstructed ion chromatogram
of the lower limit of quantification (LLOQ) and
their blank for all eight analytes
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TABLE 3 Assay performance data of all eight compounds in human plasma
Drug or metabolite Concentration (μg/L)
Within-day (n = 5) Between-day (n = 15)
Precision (CV%)Accuracy (%) Precision (CV%) Accuracy (%)
RGF LLOQ 499.9 104.6 2.2 99.6 4.4
L 1501.5 105.6 1.6 103.2 2.3
M 4505.5 103.0 1.2 100.9 1.9
H 7505.5 97.8 0.9 99.3 1.6
HLOQ 9998.0 101.9 1.0 100.8 0.9
RGF M2 LLOQ 499.8 91.3 5.6 98.5 7.4
L 1500.8 108.9 4.5 104.9 3.3
M 4502.3 104.8 4.6 104.4 0.0
H 7503.8 97.0 2.4 100.3 2.8
HLOQ 9996.0 109.1 2.6 103.2 5.2
OPR LLOQ 199.8 103.0 2.2 100.2 2.5
L 599.7 102.3 1.7 101.3 0.6
M 9595.0 102.0 1.0 100.9 1.0
H 14,992.2 98.8 1.3 99.3 0.1
HLOQ 19,975.2 101.3 1.4 100.4 0.6
NPR LLOQ 300.1 115.0 4.0 111.9 2.4
L 449.8 107.5 2.0 107.0 0.0
M 839.7 103.5 2.8 102.6 0.0
H 1499.4 98.5 2.5 99.4 0.7
HLOQ 2000.6 98.5 1.4 98.6 0.0
CBZ LLOQ 99.9 92.3 6.1 97.3 4.0
XL 300.0 106.6 3.2 104.9 1.1
L 1499.4 103.4 1.3 101.9 1.6
M 1999.2 97.8 1.7 99.1 1.5
H 3758.5 97.4 1.8 98.6 1.7
HLOQ 4997.0 102.3 1.2 100.1 2.1
VMF LLOQ 4998.70 96.8 1.9 98.1 1.4
L 14,994.9 103.1 1.0 101.0 1.9
M 43,985.0 101.9 1.3 100.1 1.5
H 74,974.5 97.9 0.9 98.3 0.3
HLOQ 99,974.0 103.3 1.6 101.3 1.7
CBT LLOQ 6.0 92.8 9.4 98.7 4.4
L 18.0 91.9 10.4 97.1 3.6
M 440.0 97.5 2.8 99.5 1.6
H 740.1 98.0 1.8 98.6 0.0
HLOQ 1000.1 98.9 2.0 99.8 0.3
DBF LLOQ 10.0 86.8 4.4 89.7 5.3
L 40.0 100.7 3.5 100.3 0.0
M 1499.9 109.0 2.2 107.6 1.0
H 2999.7 90.2 1.4 92.7 2.3
HLOQ 3999.2 97.0 1.5 99.3 2.3
Abbreviations: LLOQ, lower limit of quantification; L, low; M, medium; H, high; XL, extra low.
In cases where the between-day imprecision is 0.0%, no additional variation upon the within-day imprecision is observed as a result of performing the
assay on different days.
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4 | DISCUSSION
In this paper we described the development, validation and applica-
tion of a UPLC–MS/MS method for the quantification of vemurafenib,
cobimetinib, dabrafenib, cabozantinib, regorafenib plus metabolite
regorafenib M2, niraparib and olaparib. To our knowledge, this is the
first method which measures olaparib and niraparib in combination
with the above-mentioned analytes in a single run.
Numerous methods have been developed for the quantification
of combinations of tyrosine kinase inhibitors. One of the main difficul-
ties of the analysis of multiple tyrosine kinase inhibitors is the large
difference in clinically relevant concentrations for some of them.
Vemurafenib has a target trough concentration of 42,000 μg/L which
is several times higher than the levels of other tyrosine kinase inhibi-
tors included in our method (Goldwirt et al., 2016). Quantification
methods of vemurafenib combined with other tyrosine kinase inhibi-
tors that have been previously published, use solid-phase extraction
(Rousset et al., 2017), protein precipitation with methanol followed by
a step of evaporation (Cardoso et al., 2018) and protein precipitation
with acetonitrile and zinc-sulfate for sample preparation (Huynh et al.,
2017). An advantage of our analytical method is the simple sample
preparation by protein precipitation with acetonitrile. Although the
sample preparation is simple, limited matrix effects were observed by
this approach. The sample volume of 50 μl is equal to or less than that








4C RGF 14 104.3









Room temperature RGF 14 103.1









−40C RGF 141 101.3



















aMean recovery of the concentration range QC low to QC high (n = 6) for each analyte.
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in previously published methods (Abdelhameed et al., 2017; Cardoso
et al., 2018; Huynh et al., 2017; Luethi et al., 2014; Merienne et al.,
2018; Nijenhuis et al., 2013; Nijenhuis et al., 2014; Pressiat et al.,
2018; Rousset et al., 2017; van Andel et al., 2017; van Erp et al.,
2013).
Another major difficulty of the analysis of multiple oral oncolytics
in a single run is the wide variety in chemical characteristics of these
drugs as shown in Figure 1. For this reason, almost all of the reported
multiple tyrosine kinase inhibitors use a gradient elution system (Car-
doso et al., 2018; Huynh et al., 2017; Merienne et al., 2018; Pressiat
et al., 2018; van Erp et al., 2013). Niraparib has a relatively hydrophilic
structure and has not yet been included in a multianalyte assay to our
knowledge. In our method the analytes are separated adequately to
quantify all eight analytes with the use of a gradient system combined
with a Cortecs UPLC C18 column. This column tolerates a flow of
0.8 ml/min, which facilitates the relatively short run time of 7 min
within the range of previously described runs with multiple tyrosine
kinase inhibitors of ~5–10 min (Abdelhameed et al., 2017; Cardoso et
al., 2018; Huynh et al., 2017; Merienne et al., 2018; Pressiat et al.,
2018; van Erp et al., 2013).
An important limitation of our method is the need for a set of
nine working solutions to reach the range for the calibration stan-
dards, which is a labour-intensive approach. However, our method
TABLE 5 Stability of processed samples in the autosampler and stock solutions
Matrix Condition Component
Nominal
concentration (μg/L) n Time interval






RGF 1500 5 9 days 102.7
7500 5 98.8
RGF M2 1500 5 9 days 98.4
7500 5 97.4
OPR 600 5 9 days 101.3
15,000 5 99.5
NRP 450 5 9 days 106.4
1500 5 100.0
CBZ 500 5 9 days 99.6
3760 5 97.6
VMF 15,000 5 9 days 100.6
75,000 5 97.5
CBT 18 5 9 days 98.6
740 5 96.3




−40C RGF 1000b 3 4.8 months 102.7
RGF M2 1000 3 4.8 months 99.5
OPR 10,000b 3 4.8 months 101.0
NRP 1000b 3 4.8 months 103.1
CBZ 1000b 3 4.8 months 100.3
VMF 10,000b 3 4.8 months 97.5
CBT 1000b 3 4.8 months 100.8
DBF 1000b 3 4.8 months 91.7
aAutosampler stability was tested at 4C in order to facilitate batch preparation in advance.
bConcentrations in mg/L.
F IGURE 4 Steady-state plasma concentration–time curve of
olaparib in a patient treated with 400 mg capsules twice daily
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enables simultaneous quantification of eight chemically diverse
oral targeted anticancer drugs with a wide range of clinical concen-
trations and is therefore suitable for application in the clinical
setting.
In conclusion, we have developed and validated a robust and
UPLC–MS/MS method for the simultaneous quantification of seven
new oral anticancer drugs. The assay is used for both guidance of indi-
vidual patients and for clinical pharmacological trials in our clinic.
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